GENE ONLINE|News &
Opinion
Blog

FDA Gives Emergency Approval for Lilly’s Anti-Omicron Antibody Treatment

by Arvind C. Shekhar
Share To

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Eli Lilly’s Bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant of the SARS-CoV-2 virus. 

Related Article: AstraZeneca’s Covid-19 Booster and Antibody Cocktail Retains Neutralizing Ability against Omicron

A Neutralizing Antibody Effective Against Mutated SARS-CoV-2 Variants

 

Discovered by AbCellera and the US National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center researchers and licensed and developed by Eli Lilly, Bebtelovimab is a neutralising IgG1 monoclonal antibody (mAb), directed against the SARS-CoV-2 virus’ spike protein. It maintains binding and neutralizing activity across currently known and reported variants of concern, including Omicron and BA.2. 

Bebtelovimab can now be used as an intravenous injection (175 mg/dose) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) satisfying the following conditions: 

  • Those with positive results of direct SARS-CoV-2 viral testing, and
  • having high risk for progression to severe COVID-19, including hospitalization or death, and
  • for whom alternate COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

The data supporting this Emergency Use Authorization are primarily based on a Phase 2, randomized, clinical trial evaluating treatment of non-hospitalized patients with mild-to-moderate COVID-19 who were treated with the authorized dose of bebtelovimab (175 mg) alone or together  in combination with other mAbs like bamlanivimab and etesevimab. Pseudovirus and authentic virus testing demonstrated that bebtelovimab retains full neutralizing activity against Omicron and all other known variants of interest and concern, including BA.2.

Eli Lilly has signed an agreement with the U.S. government to supply up to 600,000 doses of bebtelovimab for at least $720 million.

“With the emergence of variants such as Omicron, treatment options remain limited. Lilly is pleased to provide another treatment option to help address the ongoing needs of patients and health care providers who continue to battle this pandemic.” said Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific and medical officer, and president of Lilly Research Laboratories. 

Related Article: GeneOnline’s Top 10 Editor’s Picks for 2021

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
EVENT
Scroll to Top